Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised and sold stock options in a paired set of transactions. On June 26 and 29, 2026, he exercised options covering 52,037 shares of common stock at exercise prices of $2.20 and $2.50 per share, then sold the same number of shares in open‑market sales around $5.00–$5.04 per share. The filing shows these trades were executed under a Rule 10b5-1 trading plan adopted on February 2, 2026, and reports that Khurram held no remaining common shares or related options from these grants immediately after the transactions.
Galectin Therapeutics Inc. (GALT) director Harold Shlevin gave notice of a proposed sale of 22,268 common shares, with an approximate sale date of June 29, 2026. The shares were acquired through a stock option exercise on January 23, 2025, with cash paid upon exercise. Shlevin also reported selling 7,732 common shares on June 26, 2026, for gross proceeds of $38,680. The notice lists August 29, 2025 as the plan adoption or instruction date for Rule 10b5-1 reliance.
Galectin Therapeutics Inc. (GALT) officer Khurram Jamil gave notice of a proposed sale of 68,287 common shares, with an aggregate market value of $341,435 and an approximate sale date of June 26, 2026. The notice lists February 2, 2026 as the date of plan adoption or giving of instruction for reliance on Rule 10b5-1. It also reports earlier sales of 568 shares on May 26, 2026, for gross proceeds of $1,761, and 7,557 shares on June 23, 2026, for gross proceeds of $23,717.
Galectin Therapeutics Inc. (GALT) director Harold Shlevin reported a proposed sale of 7,732 common shares, with an aggregate market value of $38,680 and an approximate sale date of June 26, 2026. Shlevin acquired the shares on January 23, 2025 through a stock option exercise and paid cash upon exercise.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised stock options and sold the resulting shares in a planned transaction. He exercised options to acquire 7,557 shares of common stock at $1.23 per share, then sold 7,557 shares at a weighted average price of $3.14 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026, indicating it was scheduled in advance. Following these transactions, he reported no directly held common shares and 32,500 stock options outstanding, with remaining options vesting in tranches of 16,250 on specified future dates.
GALT affiliate submitted a Form 144 notice to sell 8,125 shares of Common Stock. The filing lists an aggregate dollar amount of $25,500.00 and records a recent sale of 568 shares on 05/26/2026 for $1,761.00. The notice references a stock option exercise dated 01/23/2025 and names Stifel Nicolaus & Company Inc as broker.
Galectin Therapeutics Inc. announced positive feedback from an in person FDA Type C meeting that supports advancing its lead drug belapectin into a Phase 3 trial for patients with MASH cirrhosis and portal hypertension. The company and FDA reached alignment on the overall study design, composite primary endpoint, and regulatory framework.
The Phase 3 trial is planned as a randomized, double-blind, placebo-controlled study using a single 2 mg dose of belapectin, focusing on preventing disease progression, including the development of large esophageal varices. FDA accepted Galectin’s blinded central endoscopy review methodology and confirmed that the proposed endpoints and structure are appropriate for a traditional full approval pathway.
Galectin plans to submit the final Phase 3 protocol in the third quarter of 2026 and is pursuing potential strategic and financial partners to support the program. Belapectin holds Fast Track designation and targets a high-risk patient group with substantial unmet medical need.
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options and sold shares in a routine, pre-planned transaction. On May 26, 2026, he exercised stock options to acquire 568 shares of common stock at an exercise price of $1.23 per share, then sold 568 shares in open-market trades at a weighted average price of $3.1004 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026 and previously disclosed in a Form 10-Q filed on May 15, 2026. Following these transactions, Khurram holds no common shares directly, while remaining stock options cover 40,057 shares at a $1.23 exercise price expiring on January 23, 2035.
Galectin Therapeutics Inc. reported first-quarter 2026 results showing a smaller net loss while continuing to advance its belapectin program for MASH cirrhosis. For the three months ended March 31, 2026, net loss was $5.0 million compared with $9.6 million a year earlier, and basic and diluted net loss per share improved from $0.15 to $0.08.
Research and development expense declined to $2.2 million from $6.5 million, while general and administrative expense rose to $1.8 million from $1.4 million, leading to total operating expenses of $4.1 million versus $7.9 million. Cash and cash equivalents were $14.1 million as of March 31, 2026, down from $17.7 million at December 31, 2025, and stockholders’ deficit was $132.0 million.
Galectin Therapeutics Inc. reported a Q1 2026 net loss of $5.0 million, improved from $9.6 million a year earlier, as research and development spending declined sharply. Operating expenses fell to $4.1 million from $7.9 million, mainly from lower research and development costs.
Cash and cash equivalents were $14.1 million as of March 31, 2026, down from $17.7 million at year-end, with net cash used in operating activities of $3.9 million. The company also relies on substantial related-party financing, including convertible notes and a convertible line of credit with total borrowings and accrued interest of over $100 million, all generally convertible into common stock.
Management describes Galectin as a clinical stage biopharmaceutical company with no revenue, focused on galectin-3 inhibition for fibrotic disease and cancer. Following top-line results from its NAVIGATE trial in MASH cirrhosis, the company highlights reduced portal hypertension and biomarker improvements in certain subgroups, while noting the primary composite endpoint was not met in the overall intent-to-treat population. Management believes existing cash and an available $10 million undrawn line of credit can fund currently planned operations through May 2027.